Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC4048 | 2-Deoxy-D-glucose |
| Non-metabolizable glucose analog. Inhibits phosphorylation of glucose by hexokinase; causes depletion of cellular ATP. Also inhibits phosphoglucose isomerase (PGI) competitively. Causes cell cycle inhibition and cell death in in vitro models of hypoxia; blocks tumor cell growth in animal models. Also shown to induce the unfolded protein response (UPR). | |
| BCC4052 | (3S,4S)-Tofacitinib |
| (3S,4S)-Tofacitinib is the S-enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM. | |
| BCC4053 | VU0152100 |
| Selective positive allosteric modulator of M4 muscarinic acetylcholine receptors (mAChRs) (EC50 = 380 nM). Induces 21-fold shift in ACh potency at M4 receptor. Displays no activity at other mAChR subtypes. | |
| BCC4059 | MDL-29951 |
| Potent, selective antagonist at the glycine-NMDA site (IC50 = 140 nM against glycine binding). Displays 2500-fold selectivity for the glycine vs. glutamate binding site. | |
| BCC4063 | TCS 1102 |
| Potent, dual orexin receptor antagonist (Ki values are 0.2 and 3 nM for OX2 and OX1 receptors respectively). Inhibits ADL-orexin B-mediated locomotion following i.p. administration in vivo and blocks orexin-A (Cat.No.1455) mediated increases in feeding behaviour. Brain penetrant. | |
| BCC4087 | Angiotensin II human |
| Endogenous potent vasoconstrictor peptide. Stimulates the synthesis and release of aldosterone. | |
| BCC4098 | Marinopyrrole A |
| Mcl-1 inhibitor; disrupts Mcl-1-Bim interaction and induces Mcl-1 proteasomal degradation. Exhibits no effect on Bcl-XL-Bim interaction. Selectively induces apoptosis in Mcl-1-dependent K562 leukemia cells. Sensitizes K562 and Raji cells to ABT-737-induced apoptosis. | |
| BCC4099 | CPI-203 |
| BET bromodomain inhibitor. Downregulates Myc expression, causes G1 cell cycle arrest and attenuates cell proliferation in human pancreatic neuroendocrine tumors. Arrests the growth of T cell acute lymphoblastic leukemia cells in vitro (EC50 = 91.2 nM). Also enhances the antitumor effect of rapamycin in vitro and attenuates rapamycin induced Akt activation. Orally bioavailable. | |
